Keywords: Onyx Pharma, Carfilzomib, Refractory melanoma, EMA, FDA

Onyx Pharma expands Ph III carfilzomib study ahead of EMA filing

Article | 30 March 2011

Print This

USA-based Onyx Pharmaceuticals (Nasdaq: ONXX) says it plans to expand the Phase III European clinical trial FOCUS, which is evaluating ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in